SequelSEC

HARROW, INC. HROW

Pharmaceutical Preparations · CIK 0001360214 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$275.59M
Fiscal year ended 2026-06-30
Operating income
-$2.75M
Fiscal year ended 2026-06-30
Free cash flow
$5.02M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$1.00BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$26.97Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue3.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity19.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue7.7%11th
Operating margin11.2%85th
FCF margin15.8%83th
SBC / revenue4.6%18th
CapEx / revenue0.3%22th
Net margin-1.9%75th
Revenue YoY growth36.4%71th
Current ratio2.20x31th
Gross margin75.1%59th

HARROW, INC. (HROW) reported revenue of $275.59M and net income of -$37.23M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from HARROW, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

HARROW, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$275.59M
Cost of revenue$73.64M
Gross profit$201.96M
Operating income-$2.75M
Net income-$37.23M
Research & development$29.01M
Weighted-average diluted sharesUnavailable
Pretax income-$33.43M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$175.69M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

HARROW, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$83.89M
Total assets$416.82M
Current assets$229.31M
Total liabilities$401.97M
Current liabilities$102.17M
Total equity incl. NCI$14.84M
Temporary (mezzanine) equityUnavailable
Inventory$16.91M
Accounts receivable$118.56M
Goodwill$332.00K
Long-term debtUnavailable
Accounts payable$26.26M

Cash flow

HARROW, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$6.25M
Capital expenditures$1.24M
Investing cash flow-$23.69M
Financing cash flow$48.37M
Net change in cash$30.93M
Stock-based compensation$14.70M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$1.70M

Derived

HARROW, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$5.02M
Gross margin73.3%
Operating margin-1.0%
FCF margin1.8%
SBC / revenue5.3%
Current ratio2.24x
Revenue YoY growth21.1%
Net margin-13.5%
R&D / revenue10.5%
CapEx / revenue0.4%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HROW in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.